IQVIA Holdings Inc. (NYSE:IQV) Receives $229.13 Consensus Price Target from Analysts

IQVIA Holdings Inc. (NYSE:IQV) has been given an average rating of “Buy” by the seventeen brokerages that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $229.1250.

IQV has been the subject of a number of analyst reports. Citigroup decreased their price target on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a report on Friday, February 6th. Royal Bank Of Canada began coverage on shares of IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price on the stock. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research note on Friday, February 6th. Mizuho set a $215.00 price target on shares of IQVIA in a research note on Monday, February 23rd. Finally, Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a report on Friday, March 6th.

IQVIA Stock Up 0.0%

Shares of NYSE IQV opened at $173.28 on Friday. The stock has a fifty day moving average price of $181.31 and a 200 day moving average price of $204.74. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a market cap of $29.41 billion, a P/E ratio of 22.05, a P/E/G ratio of 1.66 and a beta of 1.39.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. During the same quarter in the previous year, the firm posted $3.12 earnings per share. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Research analysts anticipate that IQVIA will post 10.84 EPS for the current fiscal year.

Institutional Investors Weigh In On IQVIA

Hedge funds have recently bought and sold shares of the business. World Investment Advisors raised its position in shares of IQVIA by 1.4% in the 4th quarter. World Investment Advisors now owns 81,682 shares of the medical research company’s stock valued at $18,412,000 after purchasing an additional 1,162 shares in the last quarter. Farmers National Bank bought a new stake in shares of IQVIA in the fourth quarter worth $236,000. Eos Management L.P. acquired a new stake in IQVIA in the fourth quarter valued at $965,000. Corient Private Wealth LLC raised its holdings in IQVIA by 18.4% in the fourth quarter. Corient Private Wealth LLC now owns 15,358 shares of the medical research company’s stock valued at $3,462,000 after acquiring an additional 2,383 shares in the last quarter. Finally, Pure Financial Advisors LLC grew its holdings in IQVIA by 7.2% during the 4th quarter. Pure Financial Advisors LLC now owns 11,731 shares of the medical research company’s stock worth $2,644,000 after acquiring an additional 792 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.